Samsung Biologics says Plant 4 to be partially operational by end of year

CEO John Rim speaking at the company's 11th Annual General Meeting of Shareholders last Tuesday
Construction of Plant 4 – dubbed Super Plant – will be complete in 2023
Samsung Biologics has said its new “Super Plant” will be partially operational by the end of the year and fully operational by mid-2023, at which time the company is expected to hold the world’s largest biomanufacturing capacity.
Plant 4 is located in the Songdo district of Incheon, South Korea and will boast 256,000 liters total manufacturing capacity once completed, bringing the CDMO’s overall capacity to 620,000 liters. The 238,000-square-meter floorplan makes it the world's largest biopharmaceutical manufacturing facility of its kind.
The company already has a slate of deals lined up for the plant, having secured CMO contracts with three companies for five different products.
Speaking to CPHI Online, CEO John Rim said the new facility would help to meet increasing demand for biologics.
He said: "By utilizing Plant 4, the company aims to meet the increasing demand of manufacturing for large-scale biologics for a wide array of diseases, tailoring the services to the clients’ specific needs.
Having advanced smart plant technologies and flexible scale of capabilities will allow us to provide stable supply for our clients and ultimately contribute to saving the lives of patients".
Rim also addressed Plant 4 progress at last week's 11th Annual General Meeting of Shareholders, where he announced a three-pronged approach to corporate growth.
In an address to shareholders, he said “We are now venturing into the three core pillars of our multidimensional growth plan, encompassing expanded manufacturing capacity, continued advancements in business portfolio, and greater global footprint”.
The company is expected to begin construction on its fifth plant (Plant 5) this year, described by Rim as a “multi modal plant” where “we will offer services beyond the traditional mammalian monoclonal antibodies production”. The plant will also be based in Incheon and is expected to include mRNA vaccine drug substance production capabilities.
Last year the company secured a contract to perform fill-finish manufacturing of Moderna’s COVID-19 vaccine, but Samsung says the mRNA drug substance expansion is unrelated to this deal.
Additionally, the company plans to purchase land for a second Bio Campus with an expected land mass 30% greater than its current campus (Bio Campus I) in Songdo, for the construction of future large scale plants and an Open Innovation Center.
Related News
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News Welcome back to the CPHI Exhibitor Spotlight!
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News China import tax fine could cost AstraZeneca up to US$8 million
British-Swedish drugmaker AstraZeneca could find itself facing fines of up to US$8million in China due to suspected unpaid import taxes on breast cancer drug Enhertu.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance